Literature DB >> 32245729

Factors associated with the receipt and completion of whole brain radiation therapy among older adults in the United States from 2010-2013.

Zahra Ghiassi-Nejad1, Kunal K Sindhu1, Erin Moshier2, Nicole Zubizarreta2, Madhu Mazumdar2, Nathan E Goldstein3, Kavita V Dharmarajan4.   

Abstract

INTRODUCTION: Whole brain radiation therapy (WBRT) is widely used to treat patients with brain metastases. However, there is debate regarding its utility in patients with poor prognoses. In this study, we sought to characterize the use of WBRT in the United States, especially in adults aged 55 and above.
MATERIAL AND METHODS: Patients with brain metastases were identified using the National Cancer Database between 2010 and 2013. The receipt and completion of WBRT with various patient factors were correlated using multivariable logistic regression.
RESULTS: 28,422 patients with brain metastases were identified, 23,362 of whom were aged 55 or above. 14,845 patients received WBRT and 12,310 patients completed treatment. Among adults aged 55 and above, 11,945 patients received WBRT, and 9812 patients completed treatment. Patients aged 60 and above were less likely to receive WBRT, while those aged 65 and above were less likely to complete WBRT. DISCUSSION: These results suggest that WBRT may be over-utilized in the United States, especially among older adults. Better interventions to improve pre-WBRT decision-making in this population are needed to select patients who might derive benefit.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  Older adults; Whole brain radiation therapy

Mesh:

Year:  2020        PMID: 32245729     DOI: 10.1016/j.jgo.2020.03.010

Source DB:  PubMed          Journal:  J Geriatr Oncol        ISSN: 1879-4068            Impact factor:   3.599


  1 in total

1.  The influence of breast cancer subtype on survival after palliative radiation for osseous metastases.

Authors:  Mohamed K Abdelhakiem; Candice Johnstone; Carmen Bergom; Adam Currey; Jared R Robbins
Journal:  Cancer Med       Date:  2020-11-04       Impact factor: 4.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.